EDGAR Filing Documents for 0001558370-22-000616

Form 8-K - Current report:

SEC Accession No. 0001558370-22-000616

Filing Date

2022-01-31

Accepted

2022-01-31 08:20:28

Documents

Period of Report

2022-01-26

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	aytu-20220126x8k.htm iXBRL	8-K	45635
2	EX-99.1	aytu-20220126xex99d1.htm	EX-99.1	11870
3	GRAPHIC	aytu-20220126xex99d1001.jpg	GRAPHIC	3114
	Complete submission text file	0001558370-22-000616.txt		189754

Data Files

Seq	Description	Document	Type	Size
4	EX-101.SCH	aytu-20220126.xsd	EX-101.SCH	3046
5	EX-101.LAB	aytu-20220126_lab.xml	EX-101.LAB	15933
6	EX-101.PRE	aytu-20220126_pre.xml	EX-101.PRE	10064
8	EXTRACTED XBRL INSTANCE DOCUMENT	aytu-20220126x8k_htm.xml	XML	4866

Mailing Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112

Business Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112 (720) 437-6580

AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)